DEF: AngioDynamics Sets Annual Meeting Agenda, Reports FY25 Performance

AngioDynamics, Inc. announced its 2025 Annual Meeting agenda, including director elections and executive compensation votes, alongside fiscal year 2025 performance highlights showing strategic transformation progress.

Summary

• The Annual Meeting of Shareholders will be held virtually on Monday, November 10, 2025, at 12:00 p.m., Eastern Time.
• Shareholders will vote on the election of two Class I directors (James C. Clemmer and Michael E. Tarnoff, MD) for three-year terms.
• A proposal to ratify the appointment of Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending May 31, 2026, will be considered.
• Shareholders will cast a Say-on-Pay advisory vote on the approval of the compensation of named executive officers.
• For the fiscal year ended May 31, 2025, GAAP reported revenue declined 3.8% to $292.5 million, primarily due to divestitures and product discontinuations totaling $33.4 million.
• On a pro-forma basis, excluding the impact of divested products, revenue grew 8.1%.
• The Med Tech segment revenue grew 19.5% in fiscal year 2025, driven by Auryon, Mechanical Thrombectomy (AngioVac and AlphaVac), and NanoKnife products.
• Gross margin increased by 300 basis points to 53.9%.
• Net loss decreased by $150.4 million to $34.0 million, and loss per share decreased by $3.76 to $0.83.
• The executive compensation program for fiscal year 2025 had 67% of the CEO's target total compensation as performance-based.
• The Board of Directors unanimously recommends a vote FOR each proposal.

Sentiment

Score: 7

Explanation: The filing presents a mixed financial picture with GAAP revenue decline but strong pro-forma growth in key strategic segments, significant gross margin improvement, and reduced net loss. The strategic transformation and product development milestones are positive, indicating future growth potential. Executive compensation is tied to performance, and corporate governance is robust. The 0% achievement on 2023 performance share revenue target is a negative, but overall, the tone is forward-looking and highlights progress in key areas.

Positives

• Pro-forma revenue, excluding divested products, grew 8.1% in fiscal year 2025.
• Med Tech segment revenue, including Auryon, Mechanical Thrombectomy, and NanoKnife, grew significantly by 19.5% in fiscal year 2025.
• Gross margin increased by 300 basis points to 53.9% for fiscal year 2025.
• Net loss decreased by $150.4 million to $34.0 million, and loss per share decreased by $3.76 to $0.83, indicating improved financial efficiency.
• Received CE mark approval in Europe for the Auryon Atherectomy laser.
• Received CPT Category I Codes for Irreversible Electroporation (IRE) for prostate and liver lesions, effective January 2026, and for the pancreas, effective January 2027.
• Received FDA 510(k) clearance for NanoKnife Prostate Tissue Ablation.
• Published positive APEX-AV trial results in the Journal of the Society for Cardiovascular Angiography & Interventions, demonstrating the safety and efficacy of the AlphaVac F1885 System.
• The 2024 shareholder advisory vote on executive compensation received strong support, with approximately 91.9% of votes cast in favor.
• The company maintains robust corporate governance practices, including 7 of 8 independent directors and an independent, non-executive Chairman.

Negatives

• GAAP reported revenue declined 3.8% to $292.5 million in fiscal year 2025.
• GAAP reported Med Device segment revenue decreased 16.0% in fiscal year 2025.
• The company reported a net loss of $34.0 million and a loss per share of $0.83 for fiscal year 2025.
• The Fiscal 2023 Performance Share Awards achieved 0% of the cumulative revenue target, resulting in no payout for that metric.

Risks

• Forward-looking statements are subject to risks and uncertainties, as detailed in the Form 10-K for the year ended May 31, 2025.
• Global macroeconomic conditions, including inflationary pressures, consumer demand, hospital operating procedures, and workflow disruptions, continue to impact the business.
• The company operates in an extremely competitive industry, which can affect its ability to attract and retain talent and achieve business objectives.
• The value of stock options is directly tied to the appreciation of common stock, exposing holders to market fluctuations.
• Performance share awards are subject to a relative total shareholder return (TSR) modifier, introducing market comparison risk against a peer group.
• The company's clawback policy allows for the recoupment of incentive-based compensation if financial results are materially restated due to fraud or intentional misconduct by an executive.
• Severance and other benefits upon a change in control may be subject to the excise tax imposed by Section 4999 of the Internal Revenue Code.

Future Outlook

The company is continuing its strategic transformation into a growth-oriented, technology-driven entity, aiming to serve larger and faster-growing markets. Strategic research and development, along with sales and marketing investments in growth platforms during fiscal year 2025, are expected to drive revenue growth in fiscal year 2026. The receipt of CPT Category I Codes for NanoKnife System for prostate and liver (effective January 2026) and pancreas (effective January 2027) indicates future market expansion and revenue potential.

Management Comments

• "We continued our strategic transformation into a growth-oriented, technology driven company that will allow us to serve larger and faster growing markets."
• "We maintained our focus on disciplined investments in talent and technologies to drive revenue growth for our company in large, fast growing, highly profitable markets."
• "The Board of Directors unanimously believes that the election of its nominees for directors, the ratification of the appointment of AngioDynamics independent registered public accounting firm, and the approval (on an advisory basis) of the compensation of its named executive officers, are in the best interests of AngioDynamics and its shareholders, and, accordingly, recommends a vote FOR each proposal."

Industry Context

AngioDynamics operates within the highly competitive medical device industry, which is currently navigating global macroeconomic disruptions, including inflationary pressures and shifts in consumer demand and hospital operating procedures. The company's strategic transformation, focusing on high-growth technology platforms like Auryon, Mechanical Thrombectomy, and NanoKnife, aligns with a broader industry trend towards innovation and specialized, high-margin medical technologies. This strategic pivot aims to position the company in larger and faster-growing segments of the market, reflecting a common industry response to evolving healthcare needs and technological advancements.

Comparison to Industry Standards

• Executive compensation targets are generally set within a competitive range of the 50th percentile of a peer group of publicly-traded medical device companies with revenues approximately 1/3x to 3x the company's current revenue.
• The company's revenue is positioned at approximately the median of its compensation peer group at the time of selection.
• Performance share awards are subject to a relative Total Shareholder Return (TSR) modifier, comparing the company's performance against a peer group of companies with similar risk profiles.
• The TSR peer group used for pay-versus-performance analysis is the RDG SmallCap Medical Devices Index.
• The CEO pay ratio of 44 to 1 is provided, with a cautionary note that it may not be directly comparable to ratios reported by other companies due to differing methodologies and employment practices.

Management Changes

Corporate Governance

Legal Proceedings

• The Board and its committees review various areas of risk, including those associated with legal proceedings, as part of their risk oversight function.
• The Nominating, Compliance and Corporate Governance Committee reviews the company's compliance with applicable laws, rules, and regulations, including FDA, SEC, and DOJ matters.

Related Party Transactions

• There were no related party transactions pursuant to Item 404 of Regulation S-K during the fiscal year ended May 31, 2025.
• The company has a Related Person Transaction Policy, approved on July 27, 2007, requiring Audit Committee pre-approval for transactions exceeding $50,000 where related persons have a material interest.

Stakeholder Impact

• Shareholders: Directly impacted by voting on director elections, auditor ratification, and executive compensation. Potential for long-term value creation through strategic transformation and growth in Med Tech, but also exposed to market risks and the company's financial performance.
• Employees: Executive compensation programs are designed to attract, motivate, engage, and retain qualified senior executive leadership talent. Clawback policies and stock ownership guidelines affect executive incentives and accountability.
• Customers: Benefit from new product approvals (Auryon CE mark, NanoKnife FDA clearance) and positive clinical trial results (AlphaVac), indicating an expansion of innovative and effective product offerings.
• Regulatory Authorities: The company's compliance with FDA, SEC, DOJ, and international regulations is overseen by the Nominating, Compliance and Corporate Governance Committee, ensuring adherence to legal and ethical standards.

Next Steps

• Hold the Annual Meeting of Shareholders on November 10, 2025, to vote on director elections, auditor ratification, and executive compensation.
• Continue the strategic transformation into a growth-oriented, technology-driven company.
• Leverage research and development and clinical and regulatory pathway expansion for new products.
• Attract and retain top talent to support strategic goals.
• Initiate the RECOVER-AV Clinical Trial in Europe for AlphaVac.
• Initiate the AMBITION BTK RCT and Registry to generate clinical evidence for the Auryon Atherectomy System.
• Implement CPT Category I Codes for NanoKnife System for prostate and liver, effective January 2026.
• Implement CPT Category I Codes for NanoKnife System for pancreas, effective January 2027.

Key Dates

Recommendation

While AngioDynamics demonstrates promising pro-forma growth in its strategic Med Tech segment and improved gross margins, the overall GAAP revenue decline and continued net loss indicate ongoing challenges. The strategic transformation is in progress with positive product development milestones, but the 0% achievement on the 2023 performance share revenue target highlights that not all financial goals are being met. The stock's performance is tied to the success of this transformation. Investors should hold to observe the continued execution of the strategy and the impact of new product approvals and clinical trials on overall financial performance before making further commitments.

Keywords

AngioDynamics, ANGO, Proxy Statement, Annual Meeting, Shareholder Vote, Director Election, Executive Compensation, Say-on-Pay, Deloitte & Touche, Fiscal Year 2025, Financial Results, Revenue, Net Loss, Gross Margin, Med Tech, Med Device, Auryon, NanoKnife, AlphaVac, Mechanical Thrombectomy, Corporate Governance, Risk Management, Medical Devices, Healthcare, FDA, CE Mark, CPT Codes, Clinical Trials